MeSH term
Frequency | Condition_Probility | Female | 59 | 0.0 |
Humans | 306 | 0.0 |
Pregnancy | 3 | 0.0 |
Diagnosis, Differential | 2 | 0.0 |
Antineoplastic Agents/*pharmacology | 14 | 1.0 |
DNA Primers/chemistry | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 11 | 0.0 |
Flavonoids/pharmacology | 3 | 0.0 |
Growth Inhibitors/*pharmacology | 24 | 13.0 |
Interleukin-6/*pharmacology | 13 | 6.0 |
Male | 59 | 0.0 |
Peptides/*pharmacology | 51 | 25.0 |
Receptors, Cytokine/metabolism | 11 | 11.0 |
Reverse Transcriptase Polymerase Chain Reaction | 15 | 0.0 |
Signal Transduction/drug effects | 4 | 0.0 |
Transfection | 23 | 0.0 |
Calcium/metabolism | 3 | 0.0 |
Cell Line | 40 | 0.0 |
Coculture Techniques | 4 | 0.0 |
Dose-Response Relationship, Drug | 17 | 0.0 |
Enzyme Induction/drug effects | 2 | 0.0 |
Gene Expression Regulation, Enzymologic/drug effects | 5 | 3.0 |
Interferon Type II/pharmacology | 3 | 0.0 |
Peptides/pharmacology | 27 | 14.0 |
Research Support, Non-U.S. Gov't | 195 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 14 | 1.0 |
Animals | 122 | 0.0 |
Cells, Cultured | 63 | 0.0 |
Interleukin-1/pharmacology | 17 | 2.0 |
Mice | 73 | 0.0 |
Monocytes/drug effects/metabolism | 2 | 2.0 |
Mutation | 3 | 0.0 |
Peptides/genetics/*metabolism | 3 | 9.0 |
Promoter Regions (Genetics) | 10 | 0.0 |
RNA, Messenger/biosynthesis | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 67 | 0.0 |
Tumor Cells, Cultured | 70 | 0.0 |
Cell Communication/drug effects/physiology | 2 | 20.0 |
Rabbits | 5 | 0.0 |
Antigens, CD/metabolism | 11 | 1.0 |
Blotting, Northern | 14 | 0.0 |
Blotting, Western | 16 | 0.0 |
Cell Division | 21 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 20 | 1.0 |
Growth Inhibitors/biosynthesis | 2 | 25.0 |
Interleukin-6/biosynthesis | 2 | 0.0 |
Lung Neoplasms/*metabolism | 2 | 2.0 |
Lymphokines/biosynthesis | 2 | 1.0 |
MAP Kinase Kinase 1 | 3 | 1.0 |
Membrane Glycoproteins/metabolism | 11 | 1.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 3 | 1.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Phosphorylation | 20 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 4 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 8 | 0.0 |
RNA, Messenger/metabolism | 12 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 18 | 0.0 |
Signal Transduction | 29 | 0.0 |
Time Factors | 15 | 0.0 |
Trans-Activators/metabolism | 17 | 1.0 |
Cell Division/drug effects/physiology | 2 | 0.0 |
Lung/cytology/drug effects/metabolism | 2 | 25.0 |
Peptides/metabolism/*pharmacology | 5 | 20.0 |
Rats | 12 | 0.0 |
Cell Culture Techniques/methods | 2 | 0.0 |
Colony-Forming Units Assay | 4 | 0.0 |
Hematopoiesis | 2 | 0.0 |
Transplantation, Heterologous | 3 | 0.0 |
Base Sequence | 32 | 0.0 |
DNA Primers | 5 | 0.0 |
Peptides/*genetics | 6 | 6.0 |
Polymerase Chain Reaction | 7 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Adult | 44 | 0.0 |
Aged | 33 | 0.0 |
Aged, 80 and over | 10 | 0.0 |
Drug Combinations | 2 | 0.0 |
Middle Aged | 40 | 0.0 |
Receptors, Interleukin-6 | 12 | 14.0 |
Recombinant Proteins/pharmacology | 13 | 0.0 |
*Dreams | 2 | 50.0 |
Infarction, Anterior Cerebral Artery/*complications/pathology | 2 | 50.0 |
Magnetic Resonance Imaging/methods | 2 | 2.0 |
*Occipital Lobe/pathology | 2 | 50.0 |
Polysomnography/methods | 2 | 40.0 |
Sleep Disorders/*etiology/pathology | 2 | 50.0 |
Sleep, REM/physiology | 2 | 11.0 |
Amino Acid Sequence | 18 | 0.0 |
Cloning, Molecular | 12 | 0.0 |
Comparative Study | 38 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Molecular Sequence Data | 41 | 0.0 |
Repressor Proteins/genetics | 2 | 1.0 |
Drug Synergism | 16 | 1.0 |
*Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Interleukin-6/pharmacology | 16 | 5.0 |
RNA, Neoplasm/biosynthesis | 2 | 1.0 |
Cell Line, Transformed | 3 | 0.0 |
Interleukin-1/*pharmacology | 6 | 1.0 |
Interstitial Collagenase/genetics | 2 | 18.0 |
RNA, Messenger/analysis | 12 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
Exons | 2 | 0.0 |
Interleukin-6/physiology | 3 | 4.0 |
Liver/metabolism | 2 | 0.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Peptides/*physiology | 9 | 20.0 |
Protein Binding | 9 | 0.0 |
Recombinant Proteins/metabolism | 9 | 0.0 |
Trans-Activators/genetics/metabolism | 2 | 1.0 |
Gene Expression/drug effects | 4 | 0.0 |
Liver/cytology | 2 | 3.0 |
MAP Kinase Signaling System/drug effects/physiology | 2 | 6.0 |
Protein-Serine-Threonine Kinases/*metabolism | 3 | 0.0 |
Tissue Inhibitor of Metalloproteinase-1/*genetics | 2 | 12.0 |
Antigens, CD/*metabolism | 8 | 1.0 |
Cell Differentiation/drug effects | 5 | 0.0 |
Cell Division/drug effects | 30 | 0.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
Flow Cytometry | 10 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 3 | 0.0 |
Membrane Glycoproteins/*metabolism | 8 | 1.0 |
Phosphorylation/drug effects | 6 | 0.0 |
RNA, Messenger/genetics/metabolism | 5 | 0.0 |
Substrate Specificity | 3 | 0.0 |
*Autocrine Communication | 2 | 8.0 |
Immunophenotyping | 2 | 0.0 |
Cytokines/biosynthesis | 2 | 0.0 |
Growth Inhibitors/*metabolism | 8 | 14.0 |
*Interleukin-6 | 42 | 11.0 |
Lymphokines/*metabolism | 6 | 1.0 |
Peptides/*metabolism | 18 | 9.0 |
Binding Sites | 13 | 0.0 |
Binding, Competitive | 5 | 0.0 |
Cytokines/metabolism | 7 | 1.0 |
Interleukin-6/metabolism | 6 | 2.0 |
Kinetics | 14 | 0.0 |
Osmolar Concentration | 15 | 2.0 |
Protein Structure, Secondary | 3 | 0.0 |
Receptor, Ciliary Neurotrophic Factor/genetics | 2 | 33.0 |
Receptors, Interleukin-6/genetics | 2 | 33.0 |
DNA-Binding Proteins/physiology | 2 | 0.0 |
Interstitial Collagenase/*physiology | 2 | 66.0 |
Transcription Factor AP-1/physiology | 2 | 4.0 |
3T3 Cells | 5 | 0.0 |
Amino Acid Motifs | 3 | 0.0 |
Dimerization | 4 | 0.0 |
Down-Regulation | 5 | 0.0 |
Fibroblasts/metabolism | 5 | 0.0 |
Gene Expression Regulation | 8 | 0.0 |
Ligands | 3 | 0.0 |
Lysosomes/metabolism | 2 | 1.0 |
MAP Kinase Signaling System | 3 | 1.0 |
Mitogen-Activated Protein Kinases/metabolism | 7 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Precipitin Tests | 5 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
Receptors, Cytokine/*metabolism | 10 | 11.0 |
Receptors, Interleukin-6/*metabolism | 4 | 26.0 |
Transduction, Genetic | 2 | 0.0 |
Hamsters | 6 | 0.0 |
Interleukin-6/*antagonists & inhibitors/pharmacology | 2 | 33.0 |
Phosphotyrosine/metabolism | 4 | 0.0 |
*Signal Transduction/drug effects | 2 | 2.0 |
Cattle | 12 | 0.0 |
Collagen/*metabolism | 6 | 3.0 |
Growth Inhibitors/pharmacology | 19 | 12.0 |
Stromelysin 1/metabolism | 2 | 13.0 |
Leukocytes/physiology | 2 | 3.0 |
Perfusion | 2 | 0.0 |
Umbilical Veins | 4 | 0.0 |
Up-Regulation | 7 | 0.0 |
Chimeric Proteins/*metabolism | 2 | 16.0 |
Receptors, Immunologic/genetics/*metabolism | 2 | 5.0 |
Antibodies, Monoclonal/metabolism | 3 | 0.0 |
Enzyme Activation | 12 | 0.0 |
Growth Inhibitors/metabolism | 6 | 18.0 |
Immunoblotting | 2 | 0.0 |
Interleukin-6/*metabolism | 5 | 4.0 |
Lymphokines/metabolism | 5 | 2.0 |
Peptides/metabolism | 7 | 3.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 5 | 2.0 |
*Proto-Oncogene Proteins | 12 | 0.0 |
Tyrphostins/pharmacology | 3 | 2.0 |
Interstitial Collagenase/genetics/metabolism | 3 | 37.0 |
Peptides/genetics/metabolism | 4 | 9.0 |
Stromelysin 1/genetics/metabolism | 2 | 40.0 |
Tissue Inhibitor of Metalloproteinase-1/genetics/metabolism | 2 | 15.0 |
Growth Inhibitors/metabolism/pharmacology | 2 | 28.0 |
Lymphokines/metabolism/pharmacology | 2 | 15.0 |
Peptides/metabolism/pharmacology | 3 | 18.0 |
Receptors, Interleukin-6/metabolism | 3 | 11.0 |
Risk Factors | 4 | 0.0 |
Antigens, CD/genetics/metabolism | 3 | 5.0 |
Membrane Glycoproteins/genetics/metabolism | 3 | 3.0 |
Peptides/genetics/*metabolism/pharmacology | 2 | 33.0 |
Receptors, Cytokine/genetics/metabolism | 3 | 25.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 4 | 1.0 |
Mitogen-Activated Protein Kinase 3 | 7 | 1.0 |
Proteins/*physiology | 2 | 1.0 |
*Repressor Proteins | 3 | 0.0 |
Signal Transduction/*physiology | 5 | 0.0 |
*Transcription Factors | 3 | 0.0 |
Cytokines/*metabolism | 6 | 2.0 |
Proteins/metabolism | 8 | 0.0 |
Signal Transduction/physiology | 3 | 0.0 |
Blotting, Southern | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
Antigens, CD/biosynthesis | 3 | 0.0 |
Cytokines/*metabolism/pharmacology | 3 | 23.0 |
Interleukin-11/pharmacology | 4 | 16.0 |
Membrane Glycoproteins/biosynthesis | 3 | 1.0 |
Receptors, Cytokine/biosynthesis | 2 | 11.0 |
Receptors, Interleukin-6/biosynthesis | 3 | 37.0 |
Prevalence | 2 | 0.0 |
Immunohistochemistry | 9 | 0.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors | 2 | 2.0 |
Up-Regulation/drug effects/physiology | 2 | 4.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Adolescent | 10 | 0.0 |
Disease Progression | 3 | 0.0 |
Prognosis | 7 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Survival Analysis | 3 | 0.0 |
Signal Transduction/*drug effects | 4 | 1.0 |
Glioma/*pathology | 2 | 3.0 |
Mice, Nude | 5 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 4 | 0.0 |
Gene Expression | 8 | 0.0 |
NF-kappa B/metabolism | 2 | 0.0 |
Oligonucleotides, Antisense | 2 | 2.0 |
Trans-Activation (Genetics) | 5 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 18 | 0.0 |
Interleukin-1/*antagonists & inhibitors | 2 | 12.0 |
Cartilage/cytology/*metabolism | 2 | 15.0 |
Matrix Metalloproteinases/metabolism | 2 | 4.0 |
Nose | 2 | 28.0 |
Proteoglycans/metabolism | 4 | 5.0 |
Tissue Inhibitor of Metalloproteinase-1/metabolism | 2 | 7.0 |
Solubility | 6 | 0.0 |
Cytokines/*genetics | 2 | 1.0 |
Interleukin-6/*genetics | 2 | 2.0 |
Peptides/genetics | 2 | 2.0 |
Reference Values | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 7 | 0.0 |
Interleukin-1/metabolism | 3 | 1.0 |
Osteoblasts/*metabolism | 2 | 3.0 |
DNA-Binding Proteins/*metabolism | 9 | 0.0 |
Lymphokines/pharmacology | 15 | 8.0 |
MAP Kinase Signaling System/drug effects/*physiology | 2 | 5.0 |
*Milk Proteins | 11 | 2.0 |
Protein-Tyrosine Kinase/*metabolism | 11 | 1.0 |
Protein-Tyrosine-Phosphatase/metabolism | 4 | 3.0 |
Trans-Activators/*metabolism | 8 | 0.0 |
Tyrosine/metabolism | 6 | 0.0 |
DNA-Binding Proteins/genetics/physiology | 2 | 2.0 |
Gene Expression Regulation/drug effects | 7 | 0.0 |
Transcription Factors/genetics/physiology | 2 | 3.0 |
Hydrolysis | 2 | 0.0 |
Cell Cycle/drug effects | 2 | 0.0 |
*Cell Cycle Proteins | 2 | 0.0 |
DNA/biosynthesis | 2 | 0.0 |
Interleukin-6/*metabolism/pharmacology | 3 | 16.0 |
Peptides/*metabolism/pharmacology | 4 | 40.0 |
Receptors, Interleukin/genetics/metabolism | 3 | 33.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
Glioma | 2 | 2.0 |
Mitogen-Activated Protein Kinases/*metabolism | 3 | 0.0 |
Receptors, Cytokine/genetics/*physiology | 3 | 33.0 |
Enzyme Induction | 2 | 0.0 |
Genistein/pharmacology | 2 | 1.0 |
Growth Substances/*physiology | 2 | 1.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
MAP Kinase Signaling System/*drug effects | 2 | 5.0 |
C-Reactive Protein/analysis | 3 | 0.0 |
Interleukin-6/blood | 3 | 0.0 |
Peptides/*blood | 4 | 5.0 |
Antibodies, Monoclonal/pharmacology | 4 | 0.0 |
*Growth Inhibitors | 10 | 17.0 |
*Lymphokines | 13 | 29.0 |
Astrocytoma | 2 | 5.0 |
Cytokines/*pharmacology | 14 | 3.0 |
Mitogen-Activated Protein Kinase 1/*metabolism | 2 | 1.0 |
Receptors, Cytokine/physiology | 2 | 7.0 |
Transcription, Genetic/drug effects | 5 | 0.0 |
Transforming Growth Factor beta/pharmacology | 4 | 1.0 |
Adjuvants, Immunologic/*pharmacology | 2 | 1.0 |
Analysis of Variance | 3 | 0.0 |
Cell Survival/drug effects | 5 | 0.0 |
Dexamethasone/pharmacology | 7 | 1.0 |
Interleukin-6/*biosynthesis | 4 | 3.0 |
Lipopolysaccharides/pharmacology | 4 | 0.0 |
Pro-Opiomelanocortin/genetics | 2 | 11.0 |
Transcription Factors/genetics | 2 | 0.0 |
Hela Cells | 3 | 0.0 |
Mitogen-Activated Protein Kinases/*physiology | 2 | 2.0 |
Acute-Phase Proteins/metabolism | 4 | 6.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 2 | 0.0 |
*Signal Transduction | 12 | 0.0 |
Thymidine/metabolism | 3 | 0.0 |
Cytokines/*physiology | 5 | 2.0 |
Peptides/*analysis | 3 | 4.0 |
CD40 Ligand | 2 | 1.0 |
Cytokines/*blood | 3 | 0.0 |
Growth Inhibitors/blood | 3 | 30.0 |
Peptides/blood | 4 | 11.0 |
Mice, Knockout | 2 | 0.0 |
Phenotype | 7 | 0.0 |
Arthritis, Rheumatoid/*metabolism | 3 | 5.0 |
Biological Markers/analysis | 2 | 0.0 |
*Extracellular Matrix Proteins | 2 | 1.0 |
Proteoglycans/*metabolism | 5 | 7.0 |
Synovial Fluid/*chemistry | 2 | 8.0 |
COS Cells | 6 | 0.0 |
Epitopes/metabolism | 3 | 5.0 |
Models, Molecular | 4 | 0.0 |
Sequence Homology, Amino Acid | 8 | 0.0 |
Lymphokines/*pharmacology | 10 | 3.0 |
Membrane Glycoproteins/*pharmacology | 2 | 2.0 |
Swine | 7 | 0.0 |
Child | 9 | 0.0 |
Child, Preschool | 4 | 0.0 |
Gene Expression Regulation/immunology | 2 | 1.0 |
Infant | 2 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Mice, Inbred BALB C | 13 | 0.0 |
Biological Assay | 4 | 1.0 |
Chromatography, Affinity | 2 | 0.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Biopsy | 2 | 0.0 |
Interleukin-11/*biosynthesis | 2 | 100.0 |
Cytokines/pharmacology | 12 | 3.0 |
Inflammation Mediators/pharmacology | 3 | 13.0 |
Antigens, CD/*physiology | 5 | 1.0 |
Cell Differentiation | 8 | 0.0 |
Macrophages/*metabolism | 2 | 0.0 |
Membrane Glycoproteins/*physiology | 6 | 2.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Carcinoma, Hepatocellular | 6 | 1.0 |
Macromolecular Substances | 7 | 0.0 |
Receptors, Cytokine/genetics/metabolism/*physiology | 2 | 66.0 |
Receptors, Interleukin/metabolism | 2 | 3.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Cell Division/physiology | 3 | 0.0 |
Growth Inhibitors/metabolism/*pharmacology | 3 | 33.0 |
E-Selectin/biosynthesis/*genetics | 2 | 66.0 |
Gene Expression Regulation/*drug effects | 4 | 0.0 |
P-Selectin/biosynthesis/*genetics | 2 | 100.0 |
Primates | 2 | 2.0 |
Species Specificity | 6 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 4 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Peptides/*genetics/physiology | 2 | 66.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Cell Movement/drug effects | 2 | 0.0 |
Neovascularization, Physiologic/*drug effects | 2 | 2.0 |
Acute-Phase Proteins/biosynthesis | 2 | 15.0 |
Antineoplastic Agents/pharmacology | 4 | 0.0 |
alpha 1-Antitrypsin/*biosynthesis | 2 | 100.0 |
Sequence Alignment | 5 | 0.0 |
Endothelium, Vascular/cytology/metabolism | 2 | 1.0 |
Receptors, Cell Surface/physiology | 2 | 1.0 |
Vascular Endothelial Growth Factor A | 3 | 0.0 |
Vascular Endothelial Growth Factors | 3 | 0.0 |
Antigens, Tumor-Associated, Carbohydrate/*chemistry/*immunology | 2 | 100.0 |
Sheep | 9 | 1.0 |
Exercise/*physiology | 4 | 1.0 |
Plasma Volume/*physiology | 2 | 18.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
Membrane Glycoproteins/genetics/physiology | 2 | 11.0 |
Receptors, Erythropoietin/genetics/physiology | 2 | 66.0 |
Trans-Activators/*physiology | 3 | 1.0 |
English Abstract | 10 | 0.0 |
Astrocytes/cytology/drug effects/*metabolism | 2 | 15.0 |
*Gene Expression Regulation/drug effects | 2 | 1.0 |
Neoplasm Transplantation | 3 | 0.0 |
Interleukin-6/*physiology | 2 | 2.0 |
Multiple Myeloma/*pathology | 3 | 5.0 |
Ciliary Neurotrophic Factor | 15 | 12.0 |
Growth Inhibitors/*blood | 3 | 15.0 |
Interleukin-11/blood | 2 | 15.0 |
Interleukin-6/*blood | 3 | 1.0 |
Lymphokines/*blood | 3 | 1.0 |
Multiple Myeloma/*blood | 2 | 8.0 |
Nerve Tissue Proteins/blood | 2 | 22.0 |
Receptors, Interleukin-6/*blood | 2 | 15.0 |
Kidney/*physiopathology | 2 | 3.0 |
Neoplasm Proteins/*biosynthesis/genetics | 2 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
Tumor Cells, Cultured/drug effects | 5 | 0.0 |
Peptides/*secretion | 2 | 15.0 |
Blood | 4 | 2.0 |
Hemoglobins/analysis | 2 | 0.0 |
Hydrogen-Ion Concentration | 4 | 0.0 |
Peptides/analysis | 3 | 3.0 |
Glucocorticoids/pharmacology | 2 | 1.0 |
Chromosome Mapping | 4 | 0.0 |
DNA, Complementary/genetics | 4 | 0.0 |
Genes, Structural | 3 | 0.0 |
Chemistry, Physical | 3 | 2.0 |
Cytotoxicity, Immunologic | 3 | 0.0 |
Point Mutation | 2 | 0.0 |
Interleukin-6/*antagonists & inhibitors | 2 | 22.0 |
Peptides/antagonists & inhibitors | 2 | 100.0 |
Chick Embryo | 4 | 0.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
Receptors, Cytokine/*physiology | 2 | 7.0 |
Collagenases/metabolism | 2 | 5.0 |
Growth Inhibitors/*physiology | 2 | 5.0 |
Exercise Test | 2 | 0.0 |
Rehydration Solutions/*chemistry/*therapeutic use | 2 | 100.0 |
Rest/*physiology | 2 | 20.0 |
Sodium/blood | 6 | 5.0 |
Culture Media, Conditioned | 3 | 0.0 |
Leukocytes, Mononuclear/*secretion | 2 | 16.0 |
Isoflavones/pharmacology | 2 | 3.0 |
Quinones/pharmacology | 3 | 2.0 |
Transforming Growth Factor beta/metabolism | 2 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 2 | 0.0 |
Synovial Fluid/metabolism | 3 | 9.0 |
Cell Line, Tumor | 4 | 0.0 |
Genetic Vectors | 4 | 0.0 |
Peptides/*genetics/metabolism | 4 | 14.0 |
Molecular Weight | 4 | 0.0 |
Physical Endurance | 2 | 6.0 |
Genes, Reporter | 3 | 0.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins c-jun/metabolism | 2 | 1.0 |
Transcription Factor AP-1/metabolism | 5 | 1.0 |
Transcription, Genetic | 7 | 0.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
Isoenzymes/metabolism | 3 | 0.0 |
Antibodies/immunology/pharmacology | 2 | 6.0 |
Cell Differentiation/*drug effects | 3 | 1.0 |
Growth Substances/metabolism | 2 | 1.0 |
Epitopes/*immunology | 2 | 0.0 |
Luciferases/metabolism | 2 | 0.0 |
Antibody Specificity/*immunology | 3 | 11.0 |
Carbohydrates/*immunology | 3 | 30.0 |
Monocyte Chemoattractant Protein-1/*metabolism | 2 | 6.0 |
RANTES/metabolism | 2 | 3.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Cytokines/antagonists & inhibitors/*pharmacology | 2 | 40.0 |
Escherichia coli | 2 | 0.0 |
Bone Marrow/*physiology | 2 | 11.0 |
Bone Marrow Cells | 4 | 0.0 |
Carrier Proteins/pharmacology | 2 | 3.0 |
Cytoskeletal Proteins/metabolism | 2 | 0.0 |
*JNK Mitogen-Activated Protein Kinases | 3 | 3.0 |
*Mitogen-Activated Protein Kinase Kinases | 4 | 4.0 |
Phosphoproteins/metabolism | 2 | 0.0 |
Protein Kinases/metabolism | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/*metabolism | 2 | 0.0 |
Receptors, Vascular Endothelial Growth Factor | 2 | 0.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Peptides/metabolism/*physiology | 2 | 28.0 |
1-Phosphatidylinositol 3-Kinase | 2 | 1.0 |
Interleukin-4/*pharmacology | 3 | 1.0 |
Phosphotransferases (Alcohol Group Acceptor)/metabolism | 2 | 2.0 |
CHO Cells | 2 | 0.0 |
Receptors, Interleukin/*metabolism | 2 | 6.0 |
Monocyte Chemoattractant Protein-1/metabolism | 2 | 3.0 |
Gene Expression/*drug effects | 2 | 0.0 |
Receptors, Interleukin/*physiology | 2 | 8.0 |
*Peptide Biosynthesis | 2 | 6.0 |
Protein-Tyrosine Kinase/*physiology | 2 | 1.0 |
Cytokines/*analysis | 2 | 2.0 |
Regional Blood Flow | 3 | 2.0 |
Antigens, CD/physiology | 2 | 0.0 |
Receptors, Interleukin/physiology | 2 | 13.0 |
Glycoproteins/*genetics/metabolism | 2 | 5.0 |
Models, Biological | 6 | 0.0 |
Tissue Inhibitor of Metalloproteinases | 3 | 4.0 |
Interleukin-6/chemistry/*metabolism | 2 | 50.0 |
Sensitivity and Specificity | 3 | 0.0 |
Antigens, Neoplasm/*immunology | 2 | 1.0 |
Antigens, Tumor-Associated, Carbohydrate/*immunology | 4 | 21.0 |
Cytokines/pharmacology/*physiology | 2 | 8.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
Nerve Tissue Proteins/pharmacology | 2 | 4.0 |
Administration, Oral | 2 | 0.0 |
Breast Neoplasms/*therapy | 2 | 7.0 |
Cancer Vaccines/*therapeutic use | 2 | 9.0 |
Hemocyanin/*therapeutic use | 2 | 50.0 |
Liver Neoplasms | 4 | 1.0 |
Melanoma | 2 | 2.0 |
Neuroblastoma | 2 | 1.0 |
Receptor, Ciliary Neurotrophic Factor | 4 | 4.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 2 | 0.0 |
Growth Substances/*pharmacology | 2 | 0.0 |
Protein Kinases/*metabolism | 2 | 0.0 |
Mice, Inbred C57BL | 6 | 0.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Liver/*drug effects/metabolism | 2 | 4.0 |
Up-Regulation/drug effects | 4 | 1.0 |
*Glycoproteins | 2 | 0.0 |
*Immunotherapy, Active | 2 | 8.0 |
Mucins/*immunology | 6 | 27.0 |
DNA/genetics | 2 | 0.0 |
Signal Transduction/*immunology | 2 | 0.0 |
Integrins/*metabolism | 2 | 1.0 |
Melanoma/pathology/physiopathology | 2 | 50.0 |
*Receptors, Vitronectin | 2 | 14.0 |
Nerve Tissue Proteins/*pharmacology | 2 | 2.0 |
Binding Sites/genetics | 3 | 0.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
*Antigens, CD | 6 | 0.0 |
Antibodies, Monoclonal/*immunology | 3 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Mucins/immunology | 3 | 27.0 |
Tumor Markers, Biological | 2 | 0.0 |
In Vitro | 3 | 0.0 |
Interleukin-11/*pharmacology | 2 | 12.0 |
Peptides/*pharmacology/physiology | 2 | 50.0 |
Interleukin-6/*analysis | 2 | 5.0 |
Receptors, Cytokine/analysis | 2 | 13.0 |
Creatinine/blood | 2 | 0.0 |
Glycoconjugates/metabolism | 2 | 18.0 |
Membrane Glycoproteins/*metabolism/physiology | 2 | 13.0 |
Mitogen-Activated Protein Kinase 1 | 3 | 2.0 |
Phosphotyrosine | 2 | 0.0 |
Antibodies, Monoclonal | 4 | 0.0 |
Amniotic Fluid/*immunology | 2 | 22.0 |
Carbohydrate Conformation | 3 | 2.0 |
Carbohydrate Sequence | 5 | 1.0 |
Glycoproteins/*metabolism | 2 | 1.0 |
Antibody Specificity | 2 | 0.0 |
Hypersensitivity, Delayed/immunology | 2 | 3.0 |
*Chromosomes, Human, Pair 22 | 3 | 1.0 |
Cosmids | 2 | 0.0 |
Growth Inhibitors/*genetics | 3 | 6.0 |
Lymphokines/*genetics | 3 | 1.0 |
Chromosomes, Human, Pair 22 | 2 | 1.0 |
Blotting, Western/methods | 2 | 1.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Immunohistochemistry/methods | 2 | 0.0 |
*Receptors, Cytokine | 4 | 2.0 |
Receptors, Immunologic/physiology | 2 | 1.0 |
Molecular Structure | 2 | 0.0 |
Mucins/analysis | 2 | 5.0 |
*Antigens, Tumor-Associated, Carbohydrate | 2 | 11.0 |
Collagen/metabolism | 2 | 0.0 |
Protein Conformation | 3 | 0.0 |
Fetus/cytology | 2 | 3.0 |
Base Sequence/genetics | 2 | 0.0 |
Protein Binding/physiology | 2 | 0.0 |
Aldosterone/blood | 2 | 1.0 |
Atrial Natriuretic Factor/*blood | 2 | 3.0 |
Heart Rate | 3 | 1.0 |
Liver/*embryology | 3 | 20.0 |
Adsorption | 2 | 1.0 |
*Mucins | 2 | 2.0 |
*Salivary Proteins | 2 | 100.0 |
*Proteins | 2 | 0.0 |
Dinoprostone/*metabolism | 2 | 5.0 |
*Exertion | 3 | 1.0 |
Adenoviridae/*genetics | 2 | 0.0 |
Transfection/methods | 2 | 1.0 |
Argipressin/*blood | 2 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
Hepatocytes/metabolism | 2 | 2.0 |
Receptors, Interleukin-6/physiology | 2 | 22.0 |
*Down-Regulation | 2 | 0.0 |
Oxygen/blood | 2 | 1.0 |
Phosphates/blood | 2 | 3.0 |
*Physical Fitness | 2 | 5.0 |
Potassium/blood | 2 | 2.0 |
Genes, Dominant | 2 | 0.0 |
